Prosecution Insights
Last updated: November 04, 2026
Application No. 18/406,517

METHODS AND DEVICES FOR DIRECTING DISSIPATION OF A CHARGED ACTIVE AGENT AFTER ADMINISTRATION

Final Rejection §103
Filed
Jan 08, 2024
Priority
Feb 20, 2019 — provisional 62/807,929 +7 more
Examiner
DARB, HAMZA A.
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Regresar Medical Inc.
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
409 granted / 551 resolved
+4.2% vs TC avg
Strong +31% interview lift
Without
With
+31.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
39 currently pending
Career history
632
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
50.6%
+10.6% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
25.2%
-14.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 551 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Acknowledgment Claims 1-2, 11-13, 17-18, 20 are amended and field on 9/3/2026. Claim 21 is newly added and claim 3 cancelled. the amendment to claims overcome the 112 rejection in the action mailed on 5/7/2026. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-2, 5-10, 12-16, 20-21 is/are rejected under 35 U.S.C. 103 as being unpatentable over Zhang et al. (US. 20060084938A1) ("Zhang ") in view of Anderson et al. (US. 20180141982A1) ("Anderson "). Re Claim 1, Zhang discloses a device (Figs. 1-33) for directing dissipation of a therapeutic agent (¶0063) after injection (abstract, ¶00063, ¶0114), the device comprising two electrodes (110 a-b, or 112a-b, ¶0098, Fig. 1, Fig. 10a-b) spaced apart from one another on a flexible substrate (Fig. 1, Fig 10b, gap such as 114, between the electrodes and ¶0114, on a patch 100, Fig. 1, ¶0112) so that a directional electric field can be generated between the two electrodes (¶0123), the flexible substrate configured for placement against the skin of a subject (¶0079, ¶0112) comprising: a through gap (114, Fig. 1, Fig. 10b) positioned between the two electrodes sized for permitting passage of an injection device (Fig. 1, needle, ¶0112, ¶0113); or a tearaway portion positioned between the two electrodes configured to tear away to form the through gap sized for permitting passage of an injection device, but it fails to disclose that the therapeutic agent is a native botulinum toxin (BoNT). However, Anderson discloses a therapeutic agent, Clostridium toxin, with a specified isoelectric point (¶0007, ¶0054, Fig .2, Table 1, ¶0007), and that the agent can be Clostridium toxin with any type such as BONT/A, BoNT/E, BoNT/B (¶0007, ¶0054, ¶0148-¶0149), a native botulinum toxin (¶0007, ¶0007, ¶0054, ¶0151, the native Clostridium toxin or its derivative as wherein the native element is combined with one or more amino acid), a recombinant botulinum toxin (T0164), a recombinant BoNT/A (¶0249), a recombinant BoNT/E (¶0115), a recombinant BoNT/B (¶0108). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modify therapeutic agent of Zhang so that the therapeutic agent is a native botulinum toxin (BoNT) as taught by Anderson for the purpose of using a desired agent for treating desired disease and for optimizing the spread of neurotoxin and avoiding side effect (Anderson, ¶0009). Re Claim 2, Zhang discloses wherein the flexible substrate is shaped for placement above an eye of the subject and so that the through gap is positioned to permit intramuscular injection of said native BoNT at the subject's forehead ( it is capable to be placed over the eyes as skin ¶0087). Re Claim 5, Zhang embodiment of Fig. 1/10a fails to disclose wherein a first of the two electrodes is encircled by a second of the two electrodes. However, Zhang in the embodiment of Fig. 2 discloses electrodes (Fig. 4) and a first of the two electrodes (120) is encircled by a second of the two electrodes (210).. Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified the electrodes of embodiment of Fig. 1 of Zhang so that a first of the two electrodes is encircled by a second of the two electrodes as taught by the embodiment of Fig. 2 of Zhang for the purpose of using an injection needle as an electrode (Zhang, ¶0100-¶0101). Re Claim 6, Zhang discloses wherein the two electrodes are substantially parallel to one another (Fig. 10b). Re Claim 7, Zhang discloses further comprising a power supply that supplies opposing charges to the two electrodes to power the directional electric field (¶0123). Re Claim 8, Zhang discloses wherein the power supply is battery powered (¶0119 such as capacitance) and attached to a same flexible substrate as the two electrodes (¶0119). Re Claim 9, Zhang discloses wherein the power supply is configured for mounting to the subject's face or head (¶0121). Re Claim 10, Zhang discloses comprising electrode connectors that differ in shape between the two electrodes ( electric connector that connect the electrodes, Fig. 10a). Re Claim 12, Zhang discloses a method of directing dissipation of a therapeutic agent in a subject, the method comprising: applying the device of claim 1 (see rejection of claim 1) against the skin of the subject (¶0079, ¶0112), injecting the therapeutic agent through the through gap (Fig. 1), and applying opposing charges to the two electrodes (Fig. 1. ¶0123, abstract), thereby creating a directional electric field between the two electrodes (Fig. 1. ¶0123, abstract) and approximately parallel to the skin so that the polarity encourages dissipation towards one of the two electrodes and away from another (Fig. 1, ¶0088), but it fails to disclose that the therapeutic agent is a native botulinum toxin (BoNT) so that the step of injecting is injection native BoNT. However, Anderson discloses a therapeutic agent, Clostridium toxin, with a specified isoelectric point (¶0007, ¶0054, Fig .2, Table 1, ¶0007), and that the agent can be Clostridium toxin with any type such as BONT/A, BoNT/E, BoNT/B (¶0007, ¶0054, ¶0148-¶0149), a native botulinum toxin (¶0007, ¶0054, ¶0151, the native Clostridium toxin or its derivative as wherein the native element is combined with one or more amino acid), a recombinant botulinum toxin (T0164), a recombinant BoNT/A (¶0249), a recombinant BoNT/E (¶0115), a recombinant BoNT/B (¶0108). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modify therapeutic agent of Zhang so that the therapeutic agent is a native botulinum toxin (BoNT) so that the step of injecting is injection native BoNT as taught by Anderson for the purpose of using a desired agent for treating desired disease and for optimizing the spread of neurotoxin and avoiding side effect (Anderson, ¶0009). Re Claim 13, Zhang discloses using a drug (¶0063), but it fails to disclose wherein said native Botulinum is selected from group consisting of BoNT/A, BoNT/E, and BoNT/B. However, Anderson discloses a therapeutic agent, Clostridium toxin, with a specified isoelectric point (¶0007, ¶0054, Fig .2, Table 1, ¶0007), and that the agent can be Clostridium toxin with any type such as BONT/A, BoNT/E, BoNT/B (¶0007, ¶0054, ¶0148-¶0149), a native botulinum toxin (¶0007, ¶0054, ¶0151, the native Clostridium toxin or its derivative as wherein the native element is combined with one or more amino acid), a recombinant botulinum toxin (T0164), a recombinant BoNT/A (¶0249), a recombinant BoNT/E (¶0115), a recombinant BoNT/B (¶0108). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modify charged agent of Zhang so that said native Botulinum is selected from group consisting of BoNT/A, BoNT/E, and BoNT/B as taught by Anderson for the purpose of using a desired agent for treating desired disease and for optimizing the spread of neurotoxin and avoiding side effect (Anderson, ¶0009). Re Claim 14, Zhang discloses wherein the opposing charges are pulsed (¶0123). Re Claim 15, Zhang discloses wherein the device is positioned at a muscle selected from the group consisting of the galbellar area, the procerus muscle, the corrugator muscle, the frontalis muscle, the occipitalis muscle, and the trapezius muscle (any muscle, ¶0060). Re Claim 16, Zhang discloses wherein the device is positioned on the subject's face (any location in the skin include the facial skin, ¶0060). Re Claim 20, Zhang discloses a method (Figs. 1-33) for directing dissipation of a therapeutic agent (abstract, ¶00063, ¶0114), the method comprising: a) subcutaneously or intramuscularly administering the therapeutic agent into a subject (using needle 120 as in Fig. 1, needle, ¶0112, ¶0113), b) placing two electrodes against the subject's skin, the two electrodes configured to receive opposing charges to generate a directional electric field approximately parallel to the skin and at the administered therapeutic agent (110 a-b, or 112a-b, ¶0098, Fig. 1, Fig. 10a-b, ¶0123 ); and c) applying a positive charge to one of the two electrodes and a negative charge to another of the two electrodes to produce the directional electric field, thereby electrically directing dissipation of the administered therapeutic agent towards one of the two electrodes and away from the oppositely charged electrode (Fig. 1, needle, ¶0112, ¶0123, the electric filed applied to the electrode, and agent will move toward an opposite charged electrode ¶0153), but it fails to specifically disclose that the therapeutic agent is a native BoNT comprising a net negative or net positive charge at physiological pH.. However, Anderson discloses a therapeutic agent, Clostridium toxin, with a specified isoelectric point (¶0007, ¶0054, Fig .2, Table 1, ¶0007), and that the agent can be Clostridium toxin with any type such as BONT/A, BoNT/E, BoNT/B (¶0007, ¶0054, ¶0148-¶0149), a native botulinum toxin (¶0007, ¶0054, ¶0151, the native Clostridium toxin or its derivative as wherein the native element is combined with one or more amino acid) comprising a net negative or net positive charge at physiological pH (¶0040) Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modify therapeutic agent of Zhang so that s the therapeutic agent is a native BoNT comprising a net negative or net positive charge at physiological pH as taught by Anderson for the purpose of using a desired agent for treating desired disease and for optimizing the spread of neurotoxin and avoiding side effect (Anderson, ¶0009). Re Claim 21, Zhang discloses wherein the electric field is pulsed (¶0015, ¶0123). Claim(s) 4, 11, 17 is/are rejected under 35 U.S.C. 103 as being unpatentable over Zhang in view of Anderson and further in view of Mclachlan et al. (WO2021062109) (“Mclachlan”). Re Claim 4, Zhang fails to disclose wherein the flexible substrate comprises a tether that tethers the two electrodes together. However, Mclachlan discloses electrodes (Fig. 1-6b) and wherein the flexible substrate comprises a tether (40) that tethers the two electrodes together (Fig. 4, ¶0048). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified the electrodes of Zhang so that the flexible substrate comprises a tether that tethers the two electrodes together as taught by Mclachlan for the purpose of using an electrode or a portion of electrode as needed in the procedure (Mclachlan, ¶0042). Re Claim 11, Zhang discloses a device ( Figs. 1-33) for directing dissipation of a therapeutic agent after injection ( the device is configured to directed the therapeutic agent , abstract, ¶00063, ¶0114), the device comprising two electrodes (110 a-b, or 112a-b, ¶0098, Fig. 1, Fig. 10a-b, Fig. 1, Fig 10b, gap such as 114, between the electrodes and ¶0114, on a patch 100, Fig. 1, ¶0112) and further discloses that a through gap (114, Fig.1) sized to permit passage of an injection device (120), the substrate comprising an adhesive backing configured for positioning the two electrodes against the skin of a subject (¶0112) for the generation of a directional electric field (¶0123), but it is silent with regards that the therapeutic agent is a native BoNT and two electrodes is spaced apart from one another on a perforated substrate is configured to tear away to separate the two electrodes from one another, thereby forming a through gap and the substrate comprising an adhesive backing. However, Anderson discloses a therapeutic agent, Clostridium toxin, with a specified isoelectric point (¶0007, ¶0054, Fig .2, Table 1, ¶0007), and that the agent can be Clostridium toxin with any type such as BONT/A, BoNT/E, BoNT/B (¶0007, ¶0054, ¶0148-¶0149), a native botulinum toxin (¶0007, ¶0054, ¶0151, the native Clostridium toxin or its derivative as wherein the native element is combined with one or more amino acid), a recombinant botulinum toxin (T0164), a recombinant BoNT/A (¶0249), a recombinant BoNT/E (¶0115), a recombinant BoNT/B (¶0108). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modify the agent of Zhang so that the therapeutic agent is a native BoNT as taught by Anderson for the purpose of using a desired agent for treating desired disease and for optimizing the spread of neurotoxin and avoiding side effect (Anderson, ¶0009). However, Mclachlan discloses electrodes (Fig. 1-6b) and wherein two electrodes (1, 2 Fig. 4) is spaced apart from one another on a perforated substrate (40, ¶0048) is configured to tear away to separate the two electrodes from one another (¶0048), thereby forming a through gap (¶0048)and the substrate comprising an adhesive backing (¶0039). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified the electrodes of Zhang two electrodes is spaced apart from one another on a perforated substrate is configured to tear away to separate the two electrodes from one another, thereby forming a through gap and the substrate comprising an adhesive backing as taught by Mclachlan for the purpose of using an electrode or a portion of electrode as needed in the procedure (Mclachlan, ¶0042). Re Claim 17, the modified Zhang discloses method of directing dissipation of a charged active agent in a subject, the method comprising: providing the device of claim 11 (see the rejection of claim 11), and Zhang further discloses, applying the device against the skin of the subject (Fig. 1, ¶0112), injecting a therapeutic agent through the through gap (¶0099), and applying opposing charges to the two electrodes (¶0123), thereby creating a directional electric field between the two electrodes (¶0123) and approximately parallel to the skin so that the polarity encourages dissipation towards one of the two electrodes and away from another.(¶0123, Fig. 10b), but it fails to disclose that the therapeutic agent is a native BoNT and tearing the perforation to separate the two electrodes from one another. However, Anderson discloses a therapeutic agent, Clostridium toxin, with a specified isoelectric point (¶0007, ¶0054, Fig .2, Table 1, ¶0007), and that the agent can be Clostridium toxin with any type such as BONT/A, BoNT/E, BoNT/B (¶0007, ¶0054, ¶0148-¶0149), a native botulinum toxin (¶0007, ¶0054, ¶0151, the native Clostridium toxin or its derivative as wherein the native element is combined with one or more amino acid), a recombinant botulinum toxin (T0164), a recombinant BoNT/A (¶0249), a recombinant BoNT/E (¶0115), a recombinant BoNT/B (¶0108). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modify charged agent of Zhang so that the therapeutic agent is a native BoNT as taught by Anderson for the purpose of using a desired agent for treating desired disease and for optimizing the spread of neurotoxin and avoiding side effect (Anderson, ¶0009). However, Mclachlan discloses electrodes (Fig. 1-6b) and wherein two electrodes (1, 2 Fig. 4) tearing the perforation to separate the two electrodes from one another (¶0048). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified the electrodes of Zhang so that the method include the step of tearing the perforation to separate the two electrodes from one another.as taught by Mclachlan for the purpose of using an electrode or a portion of electrode as needed in the procedure (Mclachlan, ¶0042). Claim(s) 18-19 is/are rejected under 35 U.S.C. 103 as being unpatentable over Zhang in view of Anderson and further in view of Mulvihill et al. (US. 20160303360A1) ("Mulvihill "). Re Claim 18, Zhang discloses a method (Figs. 1-33) for directing dissipation of a therapeutic agent (abstract, ¶00063, ¶0114), the method comprising: a) placing two electrodes against a subject's skin (110 a-b, or 112a-b, ¶0098, Fig. 1, Fig. 10a-b ), the two electrodes configured to receive opposing charges to generate a directional electric field between the two electrodes (¶0123), and approximately parallel to the skin (Fig. 1, Fig. 10b); b) subcutaneously or intramuscularly administering the therapeutic agent between the two electrodes (using needle 120 as in Fig. 1, needle, ¶0112, ¶0113), and c) applying a positive charge to one of the two electrodes and a negative charge to another of the two electrodes to produce the directional electric field, thereby electrically directing dissipation of the administered therapeutic agent towards one of the two electrodes and away from another of the two electrodes (Fig. 1, needle, ¶0112, ¶0123, the electric filed applied to the electrode, and agent will move toward an opposite charged electrode ¶0153), but it fails to specifically disclose that the charged active agent comprising a net negative or net positive charge at physiological pH. However, Anderson discloses a therapeutic agent, Clostridium toxin, with a specified isoelectric point (¶0007, ¶0054, Fig .2, Table 1, ¶0007), and that the agent can be Clostridium toxin with any type such as BONT/A, BoNT/E, BoNT/B (¶0007, ¶0054, ¶0148-¶0149), a native botulinum toxin (¶0007, ¶0054, ¶0151, the native Clostridium toxin or its derivative as wherein the native element is combined with one or more amino acid), a recombinant botulinum toxin (T0164), a recombinant BoNT/A (¶0249), a recombinant BoNT/E (¶0115), a recombinant BoNT/B (¶0108). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modify charged agent of Zhang so that the therapeutic agent is a native BoNT as taught by Anderson for the purpose of using a desired agent for treating desired disease and for optimizing the spread of neurotoxin and avoiding side effect (Anderson, ¶0009). However, Mulvihill discloses a method for directing the therapeutic agent (abstract, Fig. 5a-11, ¶0007, ¶0073) and the therapeutic agent comprising a net negative or net positive charge at physiological pH (¶0007, ¶0073). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modify therapeutic agent of Zhang so that the charged active agent comprising a net negative or net positive charge at physiological pH as taught by Mulvihill for the purpose of using a desired agent for treating desired disease and for optimizing the spread of neurotoxin and achieving desirable effect (Mulvihill, ¶0007). Re Claim 19, Zhang discloses wherein the two electrodes are placed 1-5 cm apart from one another (¶0030, the distance between left edge of left electrode and right edge of the right electrode can be 1-2 cm). Response to Arguments Applicant's arguments filed 9/3/2026 have been fully considered but they are not persuasive. In response to applicant's argument in page 7-9that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). The applicant argues that Anderson has a modified BONT this is not persuasive in ¶0007 of Anderson discloses that native BoNT (BoNT/A) can be used as therapeutic for skin so the agent is modified to BoNT/A see also claim 13. The applicant argues on page 9-10 that cited reference are not combinable. This is found not persuasive as the device is closed in Zhang and with regards to the agent can be replaced with the one Anderson .Also, wherein Mulvihill is used to further define the structure of the electrode to have a gap which is capable to be used for injection the agent. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HAMZA A. DARB whose telephone number is (571)270-1202. The examiner can normally be reached 8:00-5:00 M-F (EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chelsea Stinson can be reached at (571) 270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HAMZA A DARB/ Examiner, Art Unit 3783 /CHELSEA E STINSON/ Supervisory Patent Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Jan 08, 2024
Application Filed
May 07, 2026
Non-Final Rejection mailed — §103
Sep 03, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778754
STIMULATION OF PENIS ERECTION
2y 4m to grant Granted Nov 03, 2026
Patent 12773526
VASCULAR ACCESS CATHETER
3y 11m to grant Granted Oct 27, 2026
Patent 12766294
CATHETER SYSTEM HAVING A NEEDLE RETRACTION MECHANISM
3y 10m to grant Granted Oct 20, 2026
Patent 12758744
CATHETER DEVICE
3y 7m to grant Granted Oct 13, 2026
Patent 12746367
PERIPHERAL INTRAVENOUS CATHETER ASSEMBLY HAVING AN EXTENSION SET
7y 1m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+31.1%)
3y 4m (~6m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 551 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month